Alzheimer's disease (AD) is a chronic neurodegenerative disorder associated with dementia as a main feature. Despite decades of thorough research in the field of AD, the pathomechanism is still not fully understood. The development of novel experimental models can help us in the discovery of both genetic and non-genetic components of disease pathogenesis. As currently available therapies in AD can provide merely moderate or only temporary symptomatic relief, there is a great demand for the development of new drugs with higher therapeutic potential.
Alzheimer's disease
Alzheimer's disease (AD) is the most common age-related, progressive neurodegenerative disorder. It usually starts with a memory loss and leads to a cognitive deficit and dementia. There are many behavioral symptoms, e.g. aggression, agitation and psychosis, which are responsible for the distressing aspect of AD and pose a great emotional, physical and economic challenge [1] [2] . AD selectively affects numerous neuronal populations involving glutamatergic neurons in the hippocampus and cortex, basal forebrain cholinergic neurons and brainstem monoaminergic neurons [3] [4] [5] and cortical synapses [6] [7] . The disease is characterized by neuropathological changes such as amyloidbeta (Aβ) plaques and neurofibrillary tangles, in the regions responsible for memory formation consisting of glutamatergic circuits. A severe reduction in mitochondrial complex IV activity suggests that an energy deficit plays a key role in the development of AD [8] . Most AD cases are sporadic and numerous heritable mutations in the amyloid-β precursor protein (AβPP), which belongs to the type 1 transmembrane family of glycoproteins, have been linked to the disease. The AβPP has a Swedish mutation, in which Lys-595 and Met-596 are replaced by Asp and Lys, respectively. This enhances the early onset and propagation of AD, and leads to the cognitive impairments associated with AD [9] . The expression of the Swedish mutation alters the overall gene expression, including AD-related kinases, phosphatases, presenilin-2, and glycogen synthase kinase-3β [10] . The cleavage of AβPP by β-and γ-secretases leads to the formation of Aβ peptides, which assemble into extracellular amyloid plaques [11] . Close correlations were reported in earlier studies between the severity of the different diseases and the degree of amyloid accumulation. It has recently become rather uncertain whether amyloid aggregates really are the basic toxic species amongst conformational forms. These may rather represent a protective mechanism by segregation of toxic intermediates in the amyloid assembly pathway [12] . Insoluble fibrillar tau-protein deposits are typically observed within the cell bodies and dendrites of the neurons [15] . These neurofibrillary tangles are the other major pathogenic marker of AD. R406W is the unique tau mutation causing AD-like dementia and tauopathy in humans and it has the special ability to reduce tau phosphorylation in cultured cells [16] [17] [18] or in vitro by recombinant glycogen synthase kinase-3β
[19].
Some in vivo models of Alzheimer's disease
The most important task at present is to develop new disease-modifying modes of treatment. Before making effort to stop or at least slow neurodegenerative processes, a better understanding of the pathophysiology of diseases is needed, which demands on better animal models. With the aid of such animal models, new disease-modifying therapies can be tested and improved. The ideal animal model should meet many requirements. However, it must be borne in mind that animal models can never be perfect. Certain biochemical and physical differences have been demonstrated in the amyloid plaques in AD patients and in AD animal models. In one of the transgenic mouse models of AD, the ATP-gated P2X7 purinergic receptor cation channel is upregulated around amyloid peptide plaques and co-localizes to microglia and astrocytes. After ischemia in the cerebral cortex of rats and also following spinal cord injury, upregulation of the P2X7 receptor subtype on the microglia occurs, while the P2X7 receptor-like immunoreactivity is enhanced in the activated microglial cells of the MS and ALS spinal cord [20] . As an in vitro model for neuroinflammation involving the application of neuron/microglia co-cultures, P2X7 receptor activation on microglia appears necessary for the microglial cellmediated injury of neurons.
In recent years, a novel triple mutant mouse model of AD (3xTgAD mice) has been generated, in which the mice exhibit age-dependent Aβ deposition and tau-pathology in the hippocampus and cerebral cortex [30] . The pathology of the disease, the specific hyperphosphorylation and the conformational changes in tau, can be better monitored than earlier. This is the first demonstration of in vivo cell death imaging. Additionally, neurons can be observed in their natural environment, together with astroglia, oligodendrocytes and microglia [31] . Because of the rapid appearance of pathologic phenotypes, transgenic zebrafish larvae can be utilized not only to monitor and understand processes of diseases in vivo, but also to test and validate drugs on a large scale [30] (Table 1) .
Mitochondrial impairment and neurodegeneration
The key cytoplasmic organelles, the mitochondria, are vital for the function and survival of neurons. These are the energy powerhouse of the cells, because they provide energy from the aerobic metabolism.
Mitochondria are both important sources and targets of reactive oxygen species (ROS). Damaged mitochondria demonstrate an increased level of generation of reactive oxidants, e.g. ROS. Healthy aging is associated with a decreased neuronal mitochondrial metabolism and recent studies suggested an altered glial mitochondrial metabolism [32] . High levels of ROS can induce mitochondria-impairing mechanisms, such as a mitochondrial permeability transition, and uncouple oxidative phosphorylation, leading eventually to cell death via apoptosis or necrosis. The mitochondrial damage can comprise a respiratory chain enzyme or mitochondrial DNA (mtDNA) impairment. Oxidative stress and damaged mtDNA in aging impair the ion homeostasis and mitochondrial energy metabolism in the neurons, thereby making them vulnerable to degeneration [33] . Dysfunctions of the mitochondrial energy metabolism contribute to the generation of ROS, disturbed Ca 2+ buffering and a reduced ATP metabolism [34] .
In the AD brain, the significantly enhanced oxidative damage may cause a mitochondrial dysfunction and abnormal dynamics, leading to an energy deficit in AD neurons [35] . The oligomeric Aβ peptide plays a crucial role in the formation of the mitochondrial permeability transition pore [36] , thereby contributing to the mitochondrial dysfunction in the AD brain [37] , including impaired ATP production and increased levels of oxidative stress. Impaired axonal transport with the proximal accumulation of mitochondria can lead to the loss of distal synapses [38] .
Altered calcium homeostasis has also been reported in AD, related to Aβ production, presenilin mutations and tau phosphorylation [39] [40] .
The role of excitotoxins in neurodegeneration
One of the major causes of the development of neurodegenerative processes is excitotoxicity, first described by Olney in 1969 [41] . During Glutamate is the major excitatory neurotransmitter in the mammalian CNS, and the principal example of an excitotoxin in the brain [42] . The abnormal function of glutamate receptors may result in an enhanced release of glutamate. The changes in glutamate uptake may elevate the extracellular concentration of glutamate accompanying the excitotoxic process [43] . Excitotoxicity can occur in consequence of endogenous excitotoxins. These substances, which can act on the receptors of cerebral excitatory amino acids, may also play important roles in the pathogenesis of certain brain disorders, e.g. AD, Parkinson's disease, HD, amyotrophic lateral sclerosis, stroke, multiple sclerosis (MS), epilepsy and migraine [44] [45] . The activation of excitatory amino acid receptors results in the selective neuronal death characteristic of these diseases [46] [47] [48] . In the pathogenesis of AD, glutamate excitotoxicity plays a key role. Neurons exposed to Aβ demonstrate increased vulnerability to this phenomenon.
Overstimulation of ion-channel glutamate receptors may result in oxidative events and these receptors are up-regulated following Aβ exposure. The glutamatergic tone and Aβ may act synergistically [49] .
Some studies suggest that in specific brain areas glutamatergic signaling is compromised by Aβ-induced modulation of synaptic glutamate receptors, resulting in an early cognitive deficit [50] . A Ca 2+ overload can raise the level of kinase activation, with the formation of neurofibrillary tangles [51] .
Drugs that block NMDA or other glutamate receptors, and also compounds that decrease glutamate release, attenuate some of the pathological symptoms in experimental models of acute and chronic neurodegenerative diseases [52] . As NMDA receptor antagonists, the glycine and polyamine site agents, NR2B subunit specific antagonists and ion channel blockers may come into consideration as they have acceptable side-effects [53] . Thus, the glycine site agent kynurenic acid (KYNA) might appear to be a good candidate, but from a pharmacological aspect, it has several disadvantages, mainly as regards the route of its administration, its elimination half-life and its penetration through the blood-brain barrier. In recent years, therefore, several new KYNA analogs or prodrugs have been designed in attempts to get round these disadvantages [54] . One of the most important groups of these compounds comprises the KYNA amides [55] , which may selectively inhibit the NR2B subunit of NMDA receptors [56] .
Summary of currently available therapies in Alzheimer's disease
Cholinesterase inhibitors can moderate AD. Through impeding of the action of acetylcholinesterase (AChE) with AChE inhibitors (AChEIs), the action of ACh and its interaction with cholinergic receptors and K + channels can be prolonged. AChEIs such as donepezil, rivastigmine and galantamine have moderate beneficial effects on memory and cognition [57] . In vitro studies have revealed that donepezil possesses a neuroprotective effect through decreasing glutamate excitotoxicity, reducing Aβ toxicity and increasing the survival of cells. In contrast, donepezil and rivastigmine offer only a symptomatic effect without neuroprotection [58] [59] .
An AChEI of natural origin, galantamine, provides protection for neurons and reduces cell death. Galantamine can increase dopaminergic neurotransmission in the hippocampus of mice [60] . In the human brain, galantamine either prevents or improves the decline of cognition and daily activities [61] .
As compared with donepezil and galantamine, rivastigmine is more effective because it can inhibit both AChE and butyrylcholinesterase. It can reduce the cortical atrophy and slow the rate of decline for as long as 5 years [62] [63] .
Memantine is an NMDA receptor antagonist [64] which inhibits the influx of Ca 2+ , thereby reducing cell damage and resulting in moderate improvements in behavior and cognition [65] . This is the only welltolerated and safe drug in clinical use for AD that targets the glutamatergic system. There are reports that memantine can inhibit the abnormal phosphorylation of tau [66] [67] . A comparative study has indicated that neither donepezil nor memantine furnishes a significant improvement in mild AD [68] . Table 2 ).
60% of the mammalian brain L-KYN content is taken up from the blood by a neutral amino acid carrier, and the remaining 40% is produced locally in the brain [72] . The rate of cerebral L-KYN production has been reported to be 0.29 nmol/g/h [73] . Its key role is to serve as a precursor of neuroprotective KYNA and the neurotoxic 3-OH-L-KYN (Figure 2 ). The level of L-KYN in the cerebrospinal fluid (CSF) does not change in AD.
L-KYN is transformed to KYNA by irreversible transamination on the action of kynurenine aminotransferases (KATs). In high, nonphysiological concentrations, KYNA has proved to be a broadspectrum endogenous antagonist of ionotropic excitatory amino acid receptors [74] . It exhibits a high affinity for the glycine-binding site of the NMDA receptor, blocking its activity in low micromolar concentrations [75] and it is additionally a weak antagonist of the AMPA/kainate receptors [76] . It has recently been demonstrated that KYNA in nanomolar concentrations displays a neuromodulatory effect, whereas in micromolar concentrations, above the physiological range, it inhibits the neuronal activity [77] [78] . Moreover, KYNA noncompetitively blocks the α7-nicotinic acetylcholine (α7-nACh) receptors and can increase the expression of non-α7-nACh receptors [79] [80] . It has been concluded that cross-talk occurs between KYNA and the cholinergic system, a situation which has been presumed to play a role in the pathogenesis of numerous brain impairments [81] . In view of its pharmacological activity, it seems to possess a neuroprotective potential, but in very high concentrations it can exert adverse effects, as exemplified by the intracerebroventricular injection of KYNA into rats, which results in reduced exploratory activity, ataxia, stereotypy, sleeping and respiratory depression [82] . Under physiological conditions, elevation in KYNA concentration can result in cognitive impairment [83] [84] . However, under pathological conditions, the situation can be different. Due to glutamate excitotoxicity, a receptor overactivation occurs, where anti-glutamatergic agents can help in setting up again the basal level of activation, promoting a memory regain in cognitive impairment.
QUIN participates in the kynurenine pathway, leading to the synthesis of the essential co-enzyme NAD + . It is present in nanomolar concentrations in the brain and exerts pronounced effects on the NMDA-sensitive subpopulation of glutamate receptors [85] . It is a weak, but specific competitive agonist of the NR2A and NR2B NMDA receptor subtypes [86] [87] . When the level of QUIN in the brain becomes elevated, it exhibits an excitatory effect at the NMDA receptors. It can provoke lipid peroxidation [88] , produce toxic free radicals [89] limiting enzyme IDO-1 were observed; this latter was shown to be specifically localized in conjunction with neurofibrillary tangles, and the association of IDO-1 with senile plaques was confirmed [98] .
Pharmacological manipulation of the kynurenine pathway with a view to the treatment of Alzheimer's disease
Abnormalities of the kynurenine pathway clearly play a crucial role in the neurodegeneration involved in various neurological and psychiatric disorders [71] . Subsequent to the availability of novel pharmacological agents, a number of interesting features of L-KYN biology have recently been discovered [54] . In another animal model, L-KYN combined with probenecid rescued the Schaffer collateral-CA1 synapses from impaired long-term potentiation induction after transient global ischemia [99] .
One of the most important treatment possibilities is the modulation of kynurenergic compounds because this can furnish one of the greatest biochemical armaments [100] . Effective inhibitors of mammalian 5,7-Dichlorokynurenic acid and 7-chlorokynurenic acid (7-Cl-KYNA) are well-known KYNA analog NMDA glycine site antagonists [104] .
5,7-Dichlorokynurenic acid did not reverse the phosphatase inhibitor okaidic acid-induced AD-type abnormal hyperphosphorylation of tau in hippocampal organotypic cultures [105] . The in situ production of 7-Cl-KYNA can be achieved through use of the blood-brain penetrable prodrug 4-chlorokynurenine (4-Cl-KYN), which is preferentially metabolized in brain areas where neurodegeneration takes place, allowing administration of a lower dosage of the drug [106] . The systemic administration of 4-Cl-KYN did prevent quinolinate-induced neurotoxicity in the hippocampus of the rat [107] . Further, 4-Cl-KYN can be transformed into 4-Cl-3-HAA, a potent, selective inhibitor of 3-HAA oxygenase [108] , and thus it can inhibit QUIN synthesis too, besides blocking the NMDA receptors. Hence, modification of the kynurenine pathway through pharmacological inhibition of the enzymes of QUIN synthesis is a rational approach via which to divert the kynurenine metabolism toward the neuroprotective KYNA [109] .
Novel chemical structures have been identified by further rational design or by screening chemical libraries (e.g. the discovery of N-(4-phenylthiazol-2-yl)benzenesulfonamides as potent kynurenine 3-hydroxylase inhibitors) [110] . Potent and specific kynureninase blockers which preferentially inhibit the mammalian enzyme were recently synthesized [111] [112] . These enzyme inhibitors have so far not been examined in vivo, but can be expected to play a crucial part in the dynamics of the kynurenine pathway metabolism [54] .
Conclusion
The search for effective treatments for neurodegenerative disorders [113] , especially for AD, is currently one of the most important topics of research relating to healthcare. Drug screening can be carried out through the use of different animal models and new biochemical targets. Table 2 .
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